Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cephalosporins + azithromycin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Cephalosporins + azithromycin is a combination therapy consisting of a cephalosporin antibiotic (such as cefixime or ceftriaxone) and the macrolide antibiotic azithromycin. Cephalosporins act by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This combination is used for the treatment of various bacterial infections where broad-spectrum coverage is desired or when mixed infections are suspected. The combination may also be used in certain clinical scenarios such as sepsis or moderate COVID-19 cases; however, evidence for improved outcomes over monotherapy varies[1][2][5]. Both agents are approved antibiotics with well-established safety profiles.
- Brand names
- Zifi-AZTaxim-AZOmnicef AZHifen-AZBrutacef AZZithrox PlusCefolac-AZAzilin PlusRitolideAzinix Plus
- Other names
- cephalosporins + azithromycin
02
Targets
PBP (Penicillin-binding protein family)Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on cephalosporins + azithromycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cephalosporins + azithromycin.